Skip to main content
Journal cover image

24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).

Publication ,  Journal Article
Piacentini, J; Bennett, S; Compton, SN; Kendall, PC; Birmaher, B; Albano, AM; March, J; Sherrill, J; Sakolsky, D; Ginsburg, G; Rynn, M ...
Published in: J Am Acad Child Adolesc Psychiatry
March 2014

OBJECTIVE: We report active treatment group differences on response and remission rates and changes in anxiety severity at weeks 24 and 36 for the Child/Adolescent Anxiety Multimodal Study (CAMS). METHOD: CAMS youth (N = 488; 74% ≤ 12 years of age) with DSM-IV separation, generalized, or social anxiety disorder were randomized to 12 weeks of cognitive-behavioral therapy (CBT), sertraline (SRT), CBT+SRT (COMB), or medication management/pill placebo (PBO). Responders attended 6 monthly booster sessions in their assigned treatment arm; youth in COMB and SRT continued on their medication throughout this period. Efficacy of COMB, SRT, and CBT (n = 412) was assessed at 24 and 36 weeks postrandomization. Youth randomized to PBO (n = 76) were offered active CAMS treatment if nonresponsive at week 12 or over follow-up and were not included here. Independent evaluators blind to study condition assessed anxiety severity, functioning, and treatment response. Concomitant treatments were allowed but monitored over follow-up. RESULTS: The majority (>80%) of acute responders maintained positive response at both weeks 24 and 36. Consistent with acute outcomes, COMB maintained advantage over CBT and SRT, which did not differ, on dimensional outcomes; the 3 treatments did not differ on most categorical outcomes over follow-up. Compared to COMB and CBT, youth in SRT obtained more concomitant psychosocial treatments, whereas those in SRT and CBT obtained more concomitant combined (medication plus psychosocial) treatment. CONCLUSIONS: COMB maintained advantage over CBT and SRT on some measures over follow-up, whereas the 2 monotherapies remained indistinguishable. The observed convergence of COMB and monotherapy may be related to greater use of concomitant treatment during follow-up among youth receiving the monotherapies, although other explanations are possible. Although outcomes were variable, most CAMS-treated youth experienced sustained treatment benefit. Clinical trial registration information-Child and Adolescent Anxiety Disorders (CAMS); URL: http://clinicaltrials.gov. Unique identifier: NCT00052078.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Acad Child Adolesc Psychiatry

DOI

EISSN

1527-5418

Publication Date

March 2014

Volume

53

Issue

3

Start / End Page

297 / 310

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Sertraline
  • Selective Serotonin Reuptake Inhibitors
  • Placebos
  • Male
  • Humans
  • Female
  • Developmental & Child Psychology
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Piacentini, J., Bennett, S., Compton, S. N., Kendall, P. C., Birmaher, B., Albano, A. M., … Walkup, J. (2014). 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). J Am Acad Child Adolesc Psychiatry, 53(3), 297–310. https://doi.org/10.1016/j.jaac.2013.11.010
Piacentini, John, Shannon Bennett, Scott N. Compton, Phillip C. Kendall, Boris Birmaher, Anne Marie Albano, John March, et al. “24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).J Am Acad Child Adolesc Psychiatry 53, no. 3 (March 2014): 297–310. https://doi.org/10.1016/j.jaac.2013.11.010.
Piacentini J, Bennett S, Compton SN, Kendall PC, Birmaher B, Albano AM, et al. 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). J Am Acad Child Adolesc Psychiatry. 2014 Mar;53(3):297–310.
Piacentini, John, et al. “24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).J Am Acad Child Adolesc Psychiatry, vol. 53, no. 3, Mar. 2014, pp. 297–310. Pubmed, doi:10.1016/j.jaac.2013.11.010.
Piacentini J, Bennett S, Compton SN, Kendall PC, Birmaher B, Albano AM, March J, Sherrill J, Sakolsky D, Ginsburg G, Rynn M, Bergman RL, Gosch E, Waslick B, Iyengar S, McCracken J, Walkup J. 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). J Am Acad Child Adolesc Psychiatry. 2014 Mar;53(3):297–310.
Journal cover image

Published In

J Am Acad Child Adolesc Psychiatry

DOI

EISSN

1527-5418

Publication Date

March 2014

Volume

53

Issue

3

Start / End Page

297 / 310

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Sertraline
  • Selective Serotonin Reuptake Inhibitors
  • Placebos
  • Male
  • Humans
  • Female
  • Developmental & Child Psychology
  • Combined Modality Therapy